Table 3.
Radiological response.
| Study | Number of patients | Extra hepatic disease allowed | Chemotherapy treatment |
Radiologic staging method | Time to restaging CT (months) | Time to restaging PET (months) |
Staging criteria | Complete response % | Partial response % | Stable disease % | Curative treatment % | Median survival (months) |
Median survival From radioembolisation (months) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anderson et al. [21] |
7 | No | Pretreatment >1 month since last course | CT | 2 | NA | OWN | 0 | 0 | 86 | NR | NR | 11 |
| Andrews et al. [34] |
17 | No | Pretreatment with 5FU or HAC FUDR | CT | 4 | NA | WHO | 0 | 29 | 29 | NR | NR | 13.8 |
| Gray et al. [30] |
36 | No | Concurrent HAC FUDR Nonprotocol also received |
CT | 3* | NA | WHO | 6 | 44 | 28 | NR | NR | 17.0 |
| Wong et al. [16] |
8 | Yes | Pretreatment with 5FU, LV, and Irinotecan | CT PET |
3 | 3 | WHO | CT 11 PET 58 |
CT 16 PET 37 |
CT 16 PET 5 |
NR | NR | NR |
| Lim et al. [3] |
32 | Yes# | Concurrent 5FU | CT | 2 | NA | RECIST | 0 | 31 | 28 | NR | NR | NR |
| Murthy et al. [29] |
9 | Yes | Variable pretreatment regimes | CT MR PET |
NR | NR | RECIST | 0 | 0 | 56 | NR | 24.6 | 4.5 |
| Lewandowski et al. [35] |
27 | No | Pretreatment with capecitabine, 5FU, LV, irinotecan, or oxaliplatin | CT PET |
3 | 3 | WHO | 0 | CT 35 PET 83 |
CT 52 |
NR | NR | 9.3 |
| Mancini et al. [36] |
35 | NR | Pretreatment based on oxaliplatinor irinotecan | CT | 1.5 | NA | RECIST | 0 | 12.5 | 75 | NR | NR | NR |
| Kennedy et al. [24] |
208 | Yes# | Pretreatment based on oxaliplatinor irinotecan | CT PET |
3 | 3 | WHO | 0 | 35 | 55 | NR | NR | 10.5 |
| Stubbs et al. [22] |
100 | Yes | Concurrent HAC 5FU | CT | 3 | NA | OWN | 1 | 73 | 20 | NR | 16.2 | 11 |
| Boppudi et al. [23] |
54 | No+ | Concurrent HAC 5FU | CT | 3 | NA | OWN WHO |
9.3 1.9 |
76 14.8 |
NR | NR | NR | 14.1 |
| Jakobs et al. [37] |
18 | No+ | NR | CT | 2–4 | NA | RECIST | 0 | 76% any response | NR | NR | NR | NR |
| Sharma et al. [5] |
20 | Yes | Concurrent Folfox4 | CT | 3 | NA | RECIST | 0 | 90 | 10 | 10% (resection) | NR | 9.3 |
| van Hazel et al. [38] |
23 | Yes# | Concurrent Irinotecan | CT | 3 | NA | RECIST | 0 | 48 | 39 | 13 | 12.2 | NR |
| Hoffmann et al. [6] |
21 | No | Variable pretreatment regimes | CT | 3 | NA | RECIST | 0 | NR | NR | 5% (RFA) | NR | NR |
| Cosimelli et al. [15] |
50 | Yes★ | Pretreatment based on oxaliplatinor irinotecan | CT | 1.5 | NA | RECIST | 2 | 22 | 24 | 4% (resection) | NM | 12.6 |
| Chua et al. [33] |
140 | Yes◯ | NR | CT | 6 | NA | RECIST | 1 | 31 | 31 | NR | 9 | NR |
| Nace et al. [31] |
51 | Yes# | Prior treatment with various regimes | CT PET |
3 | 3 | RECIST | 0 | 13 | 64 | 10.2 | ||
| Kosmider et al. [32] |
19 | Yes⊛ | FOLFOX or 5FU | CT | 2 | NA | RECIST | 11 | 74 | 5 | 5% disease free at 6 years | 29.4 | 10.4 |
NA: not applicable, NR: not recorded, HAC: hepatic artery chemotherapy, FUDR: floxuridine, 5FU: 5-fluorouracil, LV: leucovorin, FOLFOX: 5-fluorouracil, leucovorin, oxaliplatin, FOLFOX4: oxaliplatin cycle 4–12, fluorouracil, leucovorin.
*Limited by government funding, #if liver dominant site of disease, +if present counted as relative contraindication, ★limited allowed: ≤3 nodules in the same extra hepatic organ each, nodule <3 mm as assessed by a 64 slice ct [15], ◯limitedextrahepatic metastases at on site such as a solitary pulmonary metastases,⊛limitedpulmonary nodules or abdominal lymphadenopathy.